PT  - JOURNAL ARTICLE
AU  - Das, Ashis Kumar
AU  - Mishra, Shiba
AU  - Mishra, Devi Kalyan
AU  - Gopalan, Saji Saraswathy
TI  - Machine learning to predict 5-year survival among pediatric Acute Myeloid Leukemia patients and development of OSPAM-C online survival prediction tool
AID  - 10.1101/2020.04.16.20068221
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.16.20068221
4099  - http://medrxiv.org/content/early/2020/08/25/2020.04.16.20068221.short
4100  - http://medrxiv.org/content/early/2020/08/25/2020.04.16.20068221.full
AB  - Background Acute myeloid leukemia (AML) accounts for a fifth of childhood leukemia. Although survival rates for AML have greatly improved over the past few decades, they vary depending on demographic and AML type factors.Objectives To predict the five-year survival among pediatric AML patients using machine learning algorithms and deploy the best performing algorithm as an online survival prediction tool.Materials and methods Pediatric patients (0 to 14 years) with a microscopically confirmed AML were extracted from the Surveillance Epidemiology and End Results (SEER) database (2000-2011) and randomly split into training and test datasets (80/20 ratio). Four machine learning algorithms (logistic regression, support vector machine, gradient boosting, and K nearest neighbor) were trained on features to predict five-year survival. Performances of the algorithms were compared, and the best performing algorithm was deployed as an online prediction tool.Results A total of 1,477 patients met our inclusion criteria. The gradient boosting algorithm was the best performer in terms of discrimination and predictive ability. It was deployed as the online survival prediction tool named OSPAM-C (https://ashis-das.shinyapps.io/ospam/).Conclusions Our study provides a framework for the development and deployment of an online survival prediction tool for pediatric patients with AML. While external validation is needed, our survival prediction tool presents an opportunity to reach informed clinical decision-making for AML patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSEER Data https://seer.cancer.gov/